Literature DB >> 24076772

Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis.

Kremena V Star1, Vincent T Ho, Helen H Wang, Robert D Odze.   

Abstract

Mycophenolate mofetil (MMF) is a T-cell inhibitor frequently used in the treatment of acute allograft rejection. MMF may cause colitis that clinically and histologically resembles graft-versus-host disease (GVHD). The aim of this study was to evaluate a wide range of histologic features that may help differentiate MMF from GVHD-induced colitis and to validate significant features on a cohort of bone marrow transplant patients who were also taking MMF as part of their immunosuppressive regimen and developed a diarrheal illness due to colitis. Routinely processed colonic biopsies from 17 patients with MMF colitis and 40 patients with GVHD-induced colitis were evaluated for the overall grade of colitis (grades 1 to 4) and histologically for a wide range of inflammatory, epithelial, and architectural changes in a blinded manner. Statistically significant features were then tested in a cohort of 20 bone marrow transplant patients who also received MMF, and later developed a diarrheal illness. Both univariate and multivariate analyses (including receiver operating characteristic analysis) were performed. Morphologic features shown to be independently associated with MMF include the presence and quantity of lamina propria eosinophils and endocrine cell aggregates and the presence and quantity of apoptotic microabscesses, hypereosinophilic (degenerated) crypts, and crypt distortion. Eosinophils were present in all MMF patients, but apoptotic microabscesses were present in none and endocrine cell aggregates in only 1 case. When a grade-by-grade comparison was made between MMF and GVHD, grade 1 or 2 MMF also showed an increased prevalence rate and quantity of lamina propria neutrophils in comparison with grade 1 or 2 GVHD. By receiver operating characteristic analysis, a combination of lamina propria eosinophils >15 per 10 HPF, combined with a lack of endocrine cell aggregates and apoptotic microabscesses, revealed sensitivity, specificity, and positive and negative predictive values of 76%, 93%, 81%, and 90%, respectively, for identification of MMF colitis. On the basis of these data, we conclude that a variety of histologic features, in particular, eosinophils >15 per 10 HPF, lack of endocrine cell aggregates in the lamina propria, and lack of apoptotic microabscesses, can be used by pathologists to help separate MMF from GVHD-induced colitis in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24076772     DOI: 10.1097/PAS.0b013e31829ab1ef

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

Review 1.  Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Authors:  Steven Naymagon; Leonard Naymagon; Serre-Yu Wong; Huaibin Mabel Ko; Anne Renteria; John Levine; Jean-Frederic Colombel; James Ferrara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

2.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

3.  Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD.

Authors:  Claire J Detweiler; Sarah B Mueller; Anthony D Sung; Jennifer L Saullo; Vinod K Prasad; Diana M Cardona
Journal:  J Pediatr Hematol Oncol       Date:  2018-08       Impact factor: 1.289

Review 4.  Biopsy diagnosis of colitis: an algorithmic approach.

Authors:  Deepa T Patil; Robert D Odze
Journal:  Virchows Arch       Date:  2017-11-25       Impact factor: 4.064

Review 5.  Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management.

Authors:  Arvind R Murali; Subhash Chandra; Zoe Stewart; Bruce R Blazar; Umar Farooq; M Nedim Ince; Jeffrey Dunkelberg
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

6.  Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Authors:  Meagan J Bemer; Linda J Risler; Brian R Phillips; Joanne Wang; Barry E Storer; Brenda M Sandmaier; Haichuan Duan; Brianne S Raccor; Michael J Boeckh; Jeannine S McCune
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-09       Impact factor: 5.742

7.  Histologic analysis has a prognostical value in colorectal biopsies assessed for suspicion of graft-versus-host disease.

Authors:  Fanny Sauvestre; Geneviève Belleannée; Claire Bréal; Catherine Mohr; Harold IpKan Fong; Sébastien Cossin; Reza Tabrizi; Noël Milpied; Stéphane Vigouroux; Jean-François Goussot; Marion Marty
Journal:  Virchows Arch       Date:  2017-11-22       Impact factor: 4.064

8.  Graft-versus-Host Disease of the Gut: A Histologic Activity Grading System and Validation.

Authors:  David Myerson; Gideon Steinbach; Ted A Gooley; Howard M Shulman
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-19       Impact factor: 5.742

Review 9.  [Gastrointestinal tract diseases induced by medications].

Authors:  H Bläker
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

10.  Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis.

Authors:  Gianluca Moroncini; Devis Benfaremo; Alessandra Mandolesi; Armando Gabrielli
Journal:  BMJ Case Rep       Date:  2018-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.